![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Singapore To Be Home To $1.5bn AstraZeneca Production Plant
On May 20, 2024, AstraZeneca, the global biopharma company, announced plans to build a $1.5...
Laboratory-Developed Tests Set To Be Regulated By The FDA
The FDA’s final rule that solidifies its presence and authority on Laboratory-Developed Tests- LDTs goes...
AbbVie, Gilgamesh Pharma Partner on Next-Gen Psychiatric Therapies
AbbVie and Gilgamesh Pharmaceuticals entered a collaboration and option-to-license agreement to develop next-generation therapies for...
Fulcrum Enters Collaboration & License Agreement with Sanofi
Fulcrum Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing small molecules, has entered into...
Aldevron, Acuitas Partner to Expand Capabilities in mRNA LNP Encapsulation
Aldevron, a global manufacturer of DNA, RNA, and proteins used in cell and gene therapies...
Abzena Launches EpiScreen 2.0, a Next Generation Immunogenicity Tool for De-Risking the Development of...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch...
ChargePoint to expand product range by investing in a dedicated multi-million-pound single-use manufacturing facility
ChargePoint Technology, a specialist in powder and liquid transfer, has invested in a new manufacturing...
EMA Offers Plans To Enhance Availability of Vital Medicines
As the EU health ministers go on to gather in Brussels on April 23–24 in...
Market Trends: Biologics Clinical Manufacturing CDMO Service
In the ever-changing pharma and biologics sector, the Biologics Clinical Manufacturing CDMO Service market has...
CDMOs Offering Unique Options To Meet Cold Chain Demands
It is worth noting that the Cell and gene therapies- CGTs have gone on to...